Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Molecular Biology » Growth Factors-FGF » FGFR1a (IIIc) Fc, Recombinant, Human (Fibroblast Growth Factor Receptor 1 alpha, BFGFR)

FGFR1a (IIIc) Fc, Recombinant, Human (Fibroblast Growth Factor Receptor 1 alpha, BFGFR)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

The FGF family plays a central role during prenatal development and postnatal growth, and the regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. The FGF ligands bind to a family of type I transmembrane tyrosine kinase receptors which leads to dimerization and activation by sequential autophosphorylation of specific tyrosine residues. Four genes encoding structurally related FGF receptors (FGFR-1 to -4) are known. Alternative splicing of the mRNAs generates numerous multiple forms of FGFR-1 to -3. Alternate forms of FGF receptors can exhibit different specificities with respect to ligand binding. For example, the form designated as FGFR1a (IIc) interacts predominantly with FGF-acidic (FGF1) and FGF-basic (FGF2). A frequent splicing event involving FGFR-1 and -2 results in receptors containing all three Ig domains, referred to as the alpha isoform, or only IgII and IgIII, referred to as the beta isoform. Only the alpha isoform has been identified for FGFR-3 and FGFR-4. Additional splicing events for FGFR-1 to -3, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). Recombinant human FGFR1a (IIIc) is a 65.2kD protein containing 586 amino acids. Under reducing conditions, FGFR1a migrates between 100-110kD on SDS-PAGE gel.
Catalog #143329
Biological ActivityAssay#1: Determined by the dose-dependent stimulation of thymidine uptake by BaF3 cells expressing FGF receptors. The expected ED50 is ~0.5ng/ml corresponding to a specific activity of ~2x10e6 units/mg.
Assay #2: Determined by a cell proliferation assay using Balb/c 3T3 cells. The expected ED50 is ~0.1ng/ml, corresponding to a specific activity of ~1x10e7 units/mg.
AA Sequence(Monomer) RPSPTLPEQA QPWGAPVEVE SFLVHPGDLL QLRCRLRDDV QSINWLRDGV QLAESNRTRI TGEEVEVQDS VPADSGLYAC VTSSPSGSDT TYFSVNVSDA LPSSEDDDDD DDSSSEEKET DNTKPNPVAP YWTSPEKMEK KLHAVPAAKT VKFKCPSSGT PNPTLRWLKN SKEFKPDHRI GGYKVRYATW SIIMDSVVPS DKGNYTCIVE NEYGSINHTY QLDVVERSPH RPILQAGLPA NKTVALGSNV EFMCKVYSDP QPHIQWLKHI EVNGSKIGPD NLPYVQILKT AGVNTTDKEM EVLHLRNVSF EDAGEYTCLA GNSIGLSHHS AWLTVLEALE ERPAVMTSPL YLEGGPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG
CrossreactivityHuman, Mouse
Quality ControlVerified by N-terminal and Mass Spectrometry analyses (when applicable).
Endotoxin<0.1ng/ug of protein (<1EU/ug).
Protein ContentVerified by UV Spectroscopy and/or SDS-PAGE gel.
Storage and StabilityStore lyophilized products at -20°C. For reconstituted solutions of most products, we recommend short-term storage at 4°C. For longer term storage the protein solution should be stored with a carrier protein (eg. 0.1% BSA) in working aliquots and stored frozen at -20°C. Additional freeze/thaw cycles may cause some denaturation of the protein.
SourceCHO cells
Purity95% by SDS-PAGE gel and HPLC analyses.
FormSupplied as a lyophilized powder.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links